Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.67 |
| ▸ | HRH2 | P25021 | 1/20 | 0.65 |
| ▸ | HRH1 | P35367 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491850 | 0.99 | HRH3 (0.69) | HRH3HRH2HRH1KDM4EALDH1A1 | |
| SCHEMBL5488668 | 0.90 | KDM4E (0.68) | HRH3HRH2HRH1KDM4EALDH1A1 | |
| SCHEMBL5287103 | 0.89 | KDM4E (0.64) | HRH3HRH2HRH1KDM4EALDH1A1 | |
| SCHEMBL5280536 | 0.88 | HRH3 (0.62) | HRH3 | |
| SCHEMBL491570 | 0.86 | HRH3 (0.72) | HRH3HRH2HRH1KDM4EALDH1A1 | |
| SCHEMBL491823 | 0.84 | HRH3 (0.66) | HRH3KDM4EALDH1A1KMT2ALMNA | |
| SCHEMBL492239 | 0.84 | HRH3 (0.78) | HRH3HRH2HRH1KDM4EALDH1A1 | |
| SCHEMBL10818222 | 0.84 | HRH2 (0.75) | HRH3HRH2HRH1GAASMN1; SMN2 | |
| SCHEMBL5215624 | 0.83 | HRH2 (0.78) | HRH3HRH2HRH1GAASMN1; SMN2 | |
| SCHEMBL12741490 | 0.81 | SIGMAR1 (0.61) | HRH3HRH2HRH1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082353-A1 | TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082353-A1 | TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | HRH3 1/4885HRH2 3/4885HRH1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.